Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ICCC 
ImmuCell Corporation (ICCC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: ICCC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $14
1 Year Target Price $14
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -26.51% | Avg. Invested days 25 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 56.54M USD | Price to earnings Ratio 28.86 | 1Y Target Price 14 |
Price to earnings Ratio 28.86 | 1Y Target Price 14 | ||
Volume (30-day avg) 1 | Beta 0.31 | 52 Weeks Range 3.38 - 7.60 | Updated Date 10/17/2025 |
52 Weeks Range 3.38 - 7.60 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.21 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 6.23% | Operating Margin (TTM) 8.84% |
Management Effectiveness
Return on Assets (TTM) 3.02% | Return on Equity (TTM) 6.61% |
Valuation
Trailing PE 28.86 | Forward PE - | Enterprise Value 67517077 | Price to Sales(TTM) 2 |
Enterprise Value 67517077 | Price to Sales(TTM) 2 | ||
Enterprise Value to Revenue 2.39 | Enterprise Value to EBITDA 13.62 | Shares Outstanding 9045851 | Shares Floating 6016396 |
Shares Outstanding 9045851 | Shares Floating 6016396 | ||
Percent Insiders 27.89 | Percent Institutions 19.93 |
Upturn AI SWOT
ImmuCell Corporation
Company Overview
History and Background
ImmuCell Corporation was founded in 1982. Initially focused on mastitis prevention, it has evolved into a leader in natural health products for dairy and beef cattle, with a commitment to science-based solutions.
Core Business Areas
- First Defense: Provides immediate immunity to newborn calves against disease, delivered through colostrum enhancement.
- Mastitis Management: Focuses on treating mastitis in lactating dairy cows using non-antibiotic solutions such as ZymEq, reducing antibiotic usage.
Leadership and Structure
Michael F. Brigham is the President and CEO. The company operates with a functional organizational structure across manufacturing, R&D, sales, and marketing.
Top Products and Market Share
Key Offerings
- First Defense: First Defense is a line of colostrum-derived antibody products that provide passive immunity to newborn calves. Market share data is not publicly available, but it is a key product for ImmuCell. Competitors include companies offering bovine colostrum supplements and alternatives, such as Land O'Lakes and various generic colostrum products. Revenue from this product is difficult to determine precisely, as the company reports product revenue holistically.
- ZymEq: ZymEq is a non-antibiotic intramammary treatment for mastitis in lactating dairy cows. Competitors include traditional antibiotic treatments for mastitis (e.g., those from Zoetis and Merck Animal Health) and other alternative mastitis treatments. Precise market share is not publicly available. It is one of the key areas of growth for ImmuCell.
Market Dynamics
Industry Overview
The animal health industry is driven by the need for effective disease prevention and treatment solutions in livestock. There is a growing focus on antibiotic reduction and alternative therapies, driven by consumer demand and regulatory changes.
Positioning
ImmuCell is positioned as a leader in natural and non-antibiotic solutions for livestock health, differentiating itself through its focus on colostrum-based products and innovative therapies.
Total Addressable Market (TAM)
The TAM for bovine health products is estimated to be several billion USD globally. ImmuCell is positioned to capture a growing share by addressing the demand for non-antibiotic alternatives, and it is estimated that the TAM is at least 5 billion dollars with much of that being served by Zoetis and Merck Animal Health.
Upturn SWOT Analysis
Strengths
- Strong brand recognition in the colostrum market
- Focus on non-antibiotic solutions
- Proprietary technology platform
- Experienced management team
Weaknesses
- Reliance on a limited number of products
- Smaller scale compared to major animal health companies
- Geographic concentration of sales
Opportunities
- Expanding into new geographic markets
- Developing new products for other livestock species
- Partnering with larger animal health companies
- Increased focus on preventative medicine in animal husbandry
Threats
- Competition from larger animal health companies
- Changes in regulatory requirements
- Fluctuations in raw material prices
- Adoption rates of newer methods
Competitors and Market Share
Key Competitors
- ZTS
- MRK
Competitive Landscape
ImmuCell competes with much larger animal health companies with significantly greater resources. However, it differentiates itself through its focus on non-antibiotic solutions and colostrum products. This niche focus allows ImmuCell to maintain market share, despite the size disparity, and compete with more targeted and effective treatments.
Growth Trajectory and Initiatives
Historical Growth: ImmuCell's growth has been driven by increasing demand for its colostrum-based products and ZymEq product.
Future Projections: Analyst estimates vary, but generally project continued growth in revenue and profitability.
Recent Initiatives: Recent initiatives include expanding manufacturing capacity and investing in research and development of new products.
Summary
ImmuCell Corporation is a niche player in the animal health market, focused on non-antibiotic solutions for dairy and beef cattle. The company is growing, but is smaller in scale and relies on a small number of products. They have opportunities to expand into new markets, but need to be wary of competition from larger companies and regulatory changes. Their focus on natural products is in line with consumer trends.
Peer Comparison
Sources and Disclaimers
Data Sources:
- ImmuCell Corporation SEC Filings (e.g., 10-K, 10-Q)
- Industry Reports on Animal Health Market
- Analyst Reports
- Company Press Releases
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ImmuCell Corporation
Exchange NASDAQ | Headquaters Portland, ME, United States | ||
IPO Launch date 1987-04-30 | President, CEO, Treasurer, Secretary & Director Mr. Michael F. Brigham | ||
Sector Healthcare | Industry Biotechnology | Full time employees 69 | Website https://immucell.com |
Full time employees 69 | Website https://immucell.com | ||
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments: Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.